Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Olga Shtepa (Dnipropetrovsk, Ukraine), Olga Shtepa, Tetyana Pertseva, Tetyana Kireyeva. Surfactant protein D (SPD) like marker of effectiveness ofphosphatidylcholine treatment outcomes in patients (pts) with community acquired pneumonia (CAP). Eur Respir J 2015; 46: Suppl. 59, 706

Member's Comments

No comment yet.

Related content which might interest you: Surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with community acquired pneumonia (CAP) during the treatment program Source: International Congress 2014 – Clinical problems in acute and chronic lung diseases Year: 2014 Surfactant protein D (SPD) like marker of effectiveness in patients (pts) with acute exacerbations (AE) of COPD ofphosphatidylcholine treatment outcomes Source: International Congress 2015 – Different data in COPD Year: 2015 Could procalcitonin (PCT) be a marker of effectiveness of antibiotic treatment (ABT) in pregnant with not severe community-acquired pneumonia (CAP)? Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders Year: 2015 Surfactant protein D (SPD) and C-reactive protein (CRP) in patient with low respiratory tract infections (LRTI) Source: Annual Congress 2013 –Lung infections: a clinical point of view Year: 2013 Acute phase proteins (APP) and serum iron in patients (pts) with simple community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 805s Year: 2006 The difference between surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with chronic obstructive pulmonary disease acute exacerbations (AE COPD) and community acquired pneumonia (CAP) Source: International Congress 2014 – Clinical presentations Year: 2014 Biomarkers and community acquired pneumonia (CAP) severity Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia Year: 2011 Biomarkers and community acquired pneumonia (CAP) severity Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity Year: 2010 Response to the combined therapy in COPD patients (pts) with different plasma surfactant protein D (SPD) level Source: International Congress 2014 – COPD markers Year: 2014 Biological markers in hospitalised patients with community acquired pneumonia (CAP) Source: Annual Congress 2010 - The spectrum of lower respiratory tract infections: risk factors of poor outcome and diagnostic tools Year: 2010 Community acquired pneumonia (CAP) mortality and biomarkers Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia Year: 2011 I-ROAD could be efficient in predicting severity of community acquired pneumonia (CAP) or healthcare-associated-pneumonia(HCAP) Source: Annual Congress 2010 - Healthcare-associated pneumonia: ventilator-associated pneumonia and pneumonia in hospitalised patients Year: 2010 Prevalence of hyponatremia (HN) in children with community acquired pneumonia (CAP) and its relation to disease severity, outcomes Source: Virtual Congress 2021 – Acute paediatric respiratory infections Year: 2021 Serum surfactant protein D (SPD) and response to the combined therapy in patients (pts) with stable COPD Source: Annual Congress 2012 - COPD treatment and varia Year: 2012 Definition of severity and the reasons for hospitalization (RH) in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2005; 26: Suppl. 49, 641s Year: 2005 Cardiac diseases in patients with community acquired pneumonia (CAP) Source: Annual Congress 2012 - Epidemiology: risk factors and prognosis in respiratory infections Year: 2012 Procalcitonin (PCT) and C-reactive protein (CRP) as markers of the differential diagnosis of severe community acquired pneumonia (sCAP) Source: Annual Congress 2013 –Respiratory infections: a combination of problems needing early treatment Year: 2013 Plasma surfactant protein D (SP-D) in patients (pts) with stable (S) COPD and during COPD acute exacerbation (AE) Source: Annual Congress 2013 –COPD biomarkers Year: 2013 COPD: Acute exacerbation (AE) and hospitalization rate (HR) in patients with different serum surfactant protein D (SPD) level Source: Annual Congress 2012 - COPD exacerbation Year: 2012 The discriminatory value of procalcitonin (PCT) and C-reactive protein (CRP) levels in HIV-seropositive patients presenting with community acquired pneumonia (CAP) due to pulmonary tuberculosis (PTB) compared with patients with pneumococcal pneumonia Source: Eur Respir J 2004; 24: Suppl. 48, 241s Year: 2004